Gonadotrophin response to releasing hormone in post-menopausal patients with ovarian tumours.
Gonadotrophin response to intravenous administration of 100 micrograms synthetic gonadotrophin-releasing hormone (GnRH) was evaluated in 14 post-menopausal women (aged 53-77) with non-endocrine ovarian tumours and 11 post-menopausal control subjects. Neither in the case of follicle-stimulating hormone (FSH) or luteinizing hormone (LH) levels, was any significant difference seen between the mean basal levels in the tumour and the control subjects. No significant release was seen in either group as regards FSH response. The mean increases in serum FSH in the tumour patients were not significantly different from those in the control subjects. In the case of LH response, the mean percentage increases in the tumour group as well as the mean area under the curves were significantly greater (P less than 0.01) than those in the control subjects. Androstenedione and oestrone levels were also evaluated in the two groups. Significantly increased levels of these hormones were seen in the tumour group in relation to those in the control group (P less than 0.001). These data are consistent with an increased LH response to GnRH in post-menopausal patients with ovarian tumours. The augmented LH release may be related to increased steroid plasma levels.
Mango
D
D
Department of Obstetrics and Gynaecology, Catholic University, Rome, Italy.
Scirpa
P
P
Liberati
M
M
Manna
P
P
Ricci
S
S
Mancuso
S
S
D000368:Aged; D000735:Androstenedione / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008593:Menopause / Q000097:blood*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood*; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology*
D010906:Pituitary Hormone-Releasing Hormones; D004970:Estrone; D000735:Androstenedione; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone